Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
arrhythmia
beta-adrenoceptor
contractility
diastole
heart failure
inotrope
noradrenaline
omecamtiv mecarbil
relaxation
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
08
02
2021
accepted:
10
02
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
2
2022
Statut:
ppublish
Résumé
Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β
Identifiants
pubmed: 33929079
doi: 10.1002/prp2.760
pmc: PMC8085933
doi:
Substances chimiques
Adrenergic alpha-Agonists
0
omecamtiv mecarbil
2M19539ERK
Urea
8W8T17847W
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00760Informations de copyright
© 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
Cardiovasc Res. 2005 Dec 1;68(3):366-75
pubmed: 16226237
Clin Exp Pharmacol Physiol. 2007 Oct;34(10):1020-8
pubmed: 17714089
Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):60-70
pubmed: 2999616
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Biophys J. 1997 Jan;72(1):254-62
pubmed: 8994610
Science. 2011 Mar 18;331(6023):1439-43
pubmed: 21415352
Lancet. 2011 Aug 20;378(9792):676-83
pubmed: 21856481
Biochemistry. 2015 Mar 17;54(10):1963-75
pubmed: 25680381
J Biol Chem. 2017 Mar 3;292(9):3768-3778
pubmed: 28082673
Circulation. 2006 Jan 17;113(2):305-15
pubmed: 16418450
J Gen Physiol. 2013 Oct;142(4):413-23
pubmed: 24043862
J Am Coll Cardiol. 2016 Mar 29;67(12):1444-1455
pubmed: 27012405
Circulation. 2000 Oct 10;102(15):1814-21
pubmed: 11023937
Am Heart J. 2006 Apr;151(4):890.e9-15
pubmed: 16569556
BMC Cardiovasc Disord. 2018 May 21;18(1):99
pubmed: 29783950
Br J Pharmacol. 2019 Dec;176 Suppl 1:S142-S228
pubmed: 31710715
Eur Heart J. 2011 Aug;32(15):1838-45
pubmed: 21388993
Sci Rep. 2018 Feb 13;8(1):2957
pubmed: 29440728
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Circulation. 1999 Jan 5-12;99(1):65-72
pubmed: 9884381
J Am Coll Cardiol. 2019 May 14;73(18):2345-2353
pubmed: 31072579
Nat Commun. 2015 Aug 06;6:7974
pubmed: 26246073
Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec;390(12):1239-1246
pubmed: 28940010
Circ Heart Fail. 2010 Jul;3(4):522-7
pubmed: 20498236
Circ Heart Fail. 2017 Oct;10(10):
pubmed: 29030372
Biophys Rev. 2020 Aug;12(4):865-878
pubmed: 32696300
Eur Heart J. 1989 Jun;10 Suppl B:29-37
pubmed: 2572419
Circ Res. 2007 Jan 5;100(1):105-11
pubmed: 17110597
Br J Pharmacol. 2015 Sep;172(18):4506-4518
pubmed: 26140433
Cardiovasc Res. 2006 Jan;69(1):128-39
pubmed: 16225854
Heart Rhythm. 2010 Dec;7(12):1891-9
pubmed: 20868774
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
JACC Heart Fail. 2020 Apr;8(4):329-340
pubmed: 32035892
Lancet. 2016 Dec 10;388(10062):2895-2903
pubmed: 27914656
Naunyn Schmiedebergs Arch Pharmacol. 2003 Jan;367(1):10-21
pubmed: 12616336
J Biol Chem. 2018 Jun 8;293(23):9017-9029
pubmed: 29666183
Physiol Rep. 2018 Sep;6(19):e13879
pubmed: 30311442
Nat Commun. 2017 Aug 4;8(1):190
pubmed: 28775348
Mol Cell Biochem. 1996 Oct-Nov;163-164:113-23
pubmed: 8974046
Circ Res. 1986 Sep;59(3):297-309
pubmed: 2876788
Acta Physiol (Oxf). 2018 Dec;224(4):e13202
pubmed: 30338659
Lancet. 2011 Aug 20;378(9792):667-75
pubmed: 21856480
J Mol Cell Cardiol. 2015 Aug;85:262-72
pubmed: 26100051